04 March 2021
R&D is the central focus of our company, coming up with new products that solve gaps in diagnostic testing and quality control on behalf of our customers. This is how ADP developed the world's first Serum Indices Quality Control sera which combines Haemolysis, Icterus & Lipaemia in a single control.
Every day in hospital laboratories across the world, millions of patient samples are being scanned on automated analysers for compromised samples. The ‘flag’ rate for compromised samples from Serum Indices (Haemolysis, Icterus, Lipaemia) can be up to 10%. However, how do we know that the automated analysers are accurately scanning the samples for Serum Indices?
Our Serum Indices QC is the only 3rd party QC sera available on the market and is essential for any laboratory that needs to comply with national and international standards, such as ISO 15189 accreditation. The product is currently being used by hospital laboratories throughout the UK and Ireland, Europe and Australia.
**Instrument specific controls are available for Beckman, Roche, Siemens and Abbott analysers**
Contact us on 028 9336 6929 for more information.
19 February 2021
An important indicator of ovarian reserve is a blood test called Anti Mullerian Hormone. It is a very sensitive marker of ovarian reserve used by fertility clinics, with the analysis performed in the Clinical Laboratory.
The ADP Tri-Level anti-Mullerian Hormone (MIS) Quality Control set is designed to monitor the performance of AMH immunoassays. This quality control has been validated against the Roche (ECLIA) immunoassay on the Roche Cobas analysers. This is a new product that enables clinicians to have a 3rd party QC for their laboratories.
The quality control has been developed in conjunction with the Royal Victoria Hospital in Belfast, Northern Ireland. The levels have been chosen to reflect critical clinical cut-off values around 12 pmol/L, a mid assay and an elevated level of 47 pmol/L, to check the linearity of the assay.
Stored frozen, defrosted it is stable for 7 days. The kit contains 2 bottles of each level, 3 levels, and 2 mls per vial ( 2 x 3 x 2ml).
(The 2013 National Institute for Health and Care Excellence (NICE) clinical guideline for fertility and the European Society of HumanReproduction and Embryology (ESHRE) recommend AMH measurement as one method to predict ovarian response to gonadotropin stimulation  and . The NICE guideline states that AMH concentration of ≤ 0.75 ng/ml (≤ 5.4 pmol/L) indicates a low ovarian response to stimulation, whereas AMH concentration ≥3.50 ng/ml (≥ 25.0 pmol/L) indicates a high response . It follows that precise and accurate AMH measurement in these intervals is a prerequisite for reliable interpretation of AMH results in a clinical setting)
12 February 2021
PSA Ultra Low Quality Control is a product that we developed in response to numerous requests for a low level control to keep pace with the ever-increasing sensitivity of PSA assays. The control is widely used in Ireland by cancer testing centres as it is ideal for monitoring PSA levels post-prostatectomy.
The control is validated against the Roche immunoassay on the Roche Cobas® analyser.
The ‘PSA: Low level’ control is manufactured as stabilised serum from human origin. The concentrations of the QC have been chosen to ensure optimal assay performance at a critical sensitivity level.
A low level or undetectable PSA level is defined as ≤0.06 ng/mL or 0.02ng/mL by the ‘American Society for therapeutic radiology and oncology consensus panel’. As defined by the intuition it is agreed that a 6-12 month ‘undetectable PSA’ level is a prediction of disease-free survival ‘DFS’. Therefore an ultra-sensitive assay is beneficial.
Reference: Int. J. Radiation Oncology Biol. Phys Vol.37 No.5 pp 1035-1041, 1997
The control is stable up to the expiry date when stored at 2-8°c. When opened the control is stable for a period of 14 days when stored at 2-8°c. The kit size is 10 x 1ml.
Contact us for instrument specific values or further information.
03 February 2021
After months of investment, research, development and trials, ADP Diagnostics in has successfully launched its new whole blood glucose quality control, a world first. The impact of this new product is significant, in that for the first time it enables clinicians and point of care specialists to use a quality control material for POC glucose testing, that is as close as possible to a patient sample.
The whole blood glucose quality control is supplied as a 2-level control x 3 vials of each level, vials are 2ml. The control is compatible with all major manufacturers’ Glucometers and instrument specific values are available. Once opened, the vials are stable for 4 months. Vials should be stored at 2-8C.
The new whole blood glucose control is of interest to any laboratory that implements a policy of continuous improvement in clinical excellence. Using this control also enables the laboratory to comply with ISO15189 guidelines which stipulate:
“The laboratory shall use quality control materials that react to the examining system in a manner as close as possible to patient samples. Quality control materials shall be periodically examined with a frequency that is based on the stability of the procedure and the risk of harm to the patient from an erroneous result.”
(Reference: ISO 15189:2012(E): 22.214.171.124 Quality control materials)
ADP Diagnostics has built a strong reputation for innovation and clinical excellence, having already launched a number of world first quality control products including a single vial Serum Indices Quality Control, and a Xanthochromia Quality Control. The company’s products are being used throughout Ireland, UK, and several other international markets. ADP Diagnostics has become a key supplier of niche quality control sera to a number of National Quality Assessment Schemes worldwide. The control is currently being used by Labquality Finland, one of Europe’s major EQA scheme organisers.
Contact us for instrument specific values or for further information.
*The whole blood glucose quality control has been developed in association with Dr L. McGrath of Torax Biosciences.
28 January 2021
Every week there are instances in the news of continued outbreaks of Covid-19 in businesses across the country. Companies and industries where staff have to unavoidably work in close proximity are particularly susceptible to these outbreaks; industries such as food processors and construction. The impact of these can be severe as infection quickly spreads.
Covid-19 absenteeism in the workplace is having a detrimental effect on businesses throughout the country, costing millions of pounds in lost revenues and additional staffing costs. If an individual suspects that they might have Covid-19 or have come into contact with someone who has tested positive, it leads to them having to self-isolate for 10 days. Employers can mitigate against this situation by proactively testing employees.
ADP Diagnostics can supply a rapid antigen test (lateral flow) for Covid-19 which can be administered quickly and effectively in a non-laboratory setting, giving employers the ability to test staff immediately, on site. An immediate negative result would enable the individual to remain in the workplace. Alternatively, if a positive test is returned the individual can then follow procedure and seek a test at a government testing centre.
This nasal swab rapid antigen test has a greater than 96.2% sensitivity and produces a result in 15 minutes. This test kit is approved for use by the Medicines and Healthcare Regulatory Authority in the UK and is CE certified.
Contact us for more information on how our test can help to minimise your risk of outbreaks or temporary closure.